carboplatin,durvalumab,paclitaxel,olaparib,bevacizumab
astrazeneca,merck,roche
['avastin', 'imfinzi', 'duo-o', 'ovarian', 'brca']
in the phase iii duo-o trial, adding lynpara/imfinzi to chemo/avastin improved progression-free survival among patients with advanced #ovariancancer who did not have brca mutations (notable since historically parp inhibitor trials have focused on the brca+ population) #asco23 
Health journalist • Senior Reporter @PrecOncNews • Contributor @NBCNews • Stories in @voxdotcom @NatGeo • @ColumbiaJourn alum • caroline@carolinehhopkins.com